Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SGX:T14 Stock Report

Market Cap: US$3.2b

Tianjin Pharmaceutical Da Ren Tang Group Balance Sheet Health

Financial Health criteria checks 5/6

Tianjin Pharmaceutical Da Ren Tang Group has a total shareholder equity of CN¥7.0B and total debt of CN¥625.9M, which brings its debt-to-equity ratio to 8.9%. Its total assets and total liabilities are CN¥11.1B and CN¥4.0B respectively. Tianjin Pharmaceutical Da Ren Tang Group's EBIT is CN¥816.1M making its interest coverage ratio -2.7. It has cash and short-term investments of CN¥2.5B.

Key information

8.9%

Debt to equity ratio

CN¥625.93m

Debt

Interest coverage ratio-2.7x
CashCN¥2.46b
EquityCN¥7.03b
Total liabilitiesCN¥4.02b
Total assetsCN¥11.05b

Recent financial health updates

Recent updates

Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) A Risky Investment?

Nov 03
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) A Risky Investment?

Is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Expensive For A Reason? A Look At Its Intrinsic Value

Aug 08
Is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Expensive For A Reason? A Look At Its Intrinsic Value

Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) To Your Watchlist Today?

Jul 21
Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) To Your Watchlist Today?

We Think Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Can Manage Its Debt With Ease

Jun 20
We Think Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Can Manage Its Debt With Ease

If EPS Growth Is Important To You, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Presents An Opportunity

Apr 17
If EPS Growth Is Important To You, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Presents An Opportunity

Calculating The Intrinsic Value Of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Mar 01
Calculating The Intrinsic Value Of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Has A Pretty Healthy Balance Sheet

Feb 03
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Has A Pretty Healthy Balance Sheet

Financial Position Analysis

Short Term Liabilities: T14's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥3.7B).

Long Term Liabilities: T14's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥351.0M).


Debt to Equity History and Analysis

Debt Level: T14 has more cash than its total debt.

Reducing Debt: T14's debt to equity ratio has increased from 3.8% to 8.9% over the past 5 years.

Debt Coverage: T14's debt is well covered by operating cash flow (65.9%).

Interest Coverage: T14 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.